Company Overview and News
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.
Scotgold Resources Ltd is delighted to announce that a sales agreement has been signed with two of Scotland's preeminent manufacturing jewellers. This agreement covers the first refining batch (approximately 16oz) of Scottish Gold made available for jewellery (and only the second refining batch produced to date) from Scotgold's Bulk Processing Trial (BPT) at the Cononish Gold and Silver Mine.
Scotgold Resources Limited (AIM: SGZ) (the "Company") advises the resignation of Mr Gabriel Chiappini, Non-Executive Director and Company Secretary of the Company, with effect from 16 May 2017. The Board wishes to thank Mr Chiappini for his contribution to the Company and wishes him well in his future endeavours.
Scotgold Resources Limited (AIM: SGZ) ("Scotgold" or the "Company") announces that 179,784 fully paid ordinary Scotgold shares ("Option Shares") have been issued on conversion of options exercisable at £0.01 on or before 30 September 2017.
Your Directors submit the financial report of Scotgold Resources Limited and Controlled Entities (the "Company" or the "Group") for the half-year ended 31 December 2016. In order to comply with the provisions of the Corporations Act 2001, the Directors report as follows:
Scotgold Resources Ltd today held a successful auction in Edinburgh of Scottish Gold; gold mined and processed at its Cononish Gold and Silver Mine near Tyndrum. This Scottish gold is the first gold ever mined commercially in Scotland. The gold was sold in the form of "Rounds", each stamped with the Scottish Gold Mark of the stag's head and bearing a unique serial number corresponding to a chain of custody system certified by the Edinburgh Assay Office.
Scotgold Resources Limited announces that its Annual General Meeting ("AGM") will be held at 9am on 29 November 201 at the New Library Room, Royal College of Physicians of Edinburgh,9 Queen Street, Edinburgh, EH2 1JQ. The Notice of Meeting has been sent to shareholders.
Scotland-focused gold miner Scotgold Resources Limited (LON:SGZ) is offering investors the chance to own the first pour of Scottish gold from its Cononish mine in Tyndrum. Chief executive Richard Gray tells Proactive: ''This is a triple-first for us -it's the first gold from Cononish mine - it's the first gold Scotgold resources has produced and importantly it's also the first commercial gold ever mined in Scotland so we felt we needed to do something to mark the event.
Further to the announcements dated 18 August and 20 September 2016, Scotgold Resources Limited (ASX:SGZ; AIM:SGZ) confirms that the Company has now ceased trading on the ASX and that the Company will be delisted from the ASX official list today at 4pm (Sydney time) on 21 October 2016.
Scotgold Resources Limited (ASX: SGZ, AIM: SGZ) announces that following the issue of 56,100,000 fully paid ordinary Scotgold shares ("New Shares"), announced on 23 September 2016, application for the New Shares to be admitted to trading on AIM ("Admission") has been made and Admission is expected to take place on 30 September 2016.
Scotgold Resouces Limited (ASX:SGZ, AIM: SGZ) announces the issue of 56,100,000 fully paid ordinary Scotgold shares following the conversion of convertible notes held by Nat le Roux. The conversion of these convertible notes was previously approved by shareholders at the meeting on 30 July 2014.
2018-04-25 - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
2018-04-25 - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...